-
1
-
-
0025916196
-
Prognosis and breast cancer. Recognition of lethal and favourable prognostic types
-
COI: 1:STN:280:DyaK3M7nsVWisA%3D%3D, PID: 2006713
-
Page DL (1991) Prognosis and breast cancer. Recognition of lethal and favourable prognostic types. Am J Surg Pathol 15:334–349
-
(1991)
Am J Surg Pathol
, vol.15
, pp. 334-349
-
-
Page, D.L.1
-
2
-
-
0021261333
-
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination
-
COI: 1:STN:280:DyaL2c3jtF2jtw%3D%3D, PID: 6733019
-
Koscielny S, Tubiana M, Lê MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715
-
(1984)
Br J Cancer
, vol.49
, pp. 709-715
-
-
Koscielny, S.1
Tubiana, M.2
Lê, M.G.3
-
3
-
-
0024460767
-
Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years
-
COI: 1:STN:280:DyaL1MzmtFGmtQ%3D%3D, PID: 2549203
-
Rosen PP, Groshen S, Saigo PE et al (1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239–1251
-
(1989)
J Clin Oncol
, vol.7
, pp. 1239-1251
-
-
Rosen, P.P.1
Groshen, S.2
Saigo, P.E.3
-
4
-
-
0024533068
-
Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases
-
COI: 1:STN:280:DyaL1M%2FovFCqug%3D%3D, PID: 2910416
-
Carter CL, Allen C, Henson DE (1989) Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187
-
(1989)
Cancer
, vol.63
, pp. 181-187
-
-
Carter, C.L.1
Allen, C.2
Henson, D.E.3
-
5
-
-
0026072872
-
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
-
COI: 1:STN:280:DyaK38%2FpvVSltw%3D%3D, PID: 1757079
-
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
-
(1991)
Histopathology
, vol.19
, pp. 403-410
-
-
Elston, C.W.1
Ellis, I.O.2
-
6
-
-
0026808390
-
The Nottingham Prognostic Index in primary breast cancer
-
COI: 1:STN:280:DyaK3s%2FgsVyisA%3D%3D, PID: 1391987
-
Galea MH, Blamey RW, Elston CE et al (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219
-
(1992)
Breast Cancer Res Treat
, vol.22
, pp. 207-219
-
-
Galea, M.H.1
Blamey, R.W.2
Elston, C.E.3
-
7
-
-
34248595234
-
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
-
PID: 17453008
-
de Azambuja E, Cardoso F, de Castro Jr G et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504–1513
-
(2007)
Br J Cancer
, vol.96
, Issue.10
, pp. 1504-1513
-
-
de Azambuja, E.1
Cardoso, F.2
de Castro Jr, G.3
-
8
-
-
68049137869
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
-
PID: 19621070
-
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100
-
(2009)
PLoS Med
, vol.6
, pp. 1000100
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
-
10
-
-
84855464719
-
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
-
PID: 22225836
-
Aleskandarany MA, Green AR, Benhasouna AA et al (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3
-
(2012)
Breast Cancer Res
, vol.14
, Issue.1
, pp. 3
-
-
Aleskandarany, M.A.1
Green, A.R.2
Benhasouna, A.A.3
-
11
-
-
57149103724
-
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole
-
PID: 18981464
-
Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26(34):5569–5575
-
(2008)
J Clin Oncol
, vol.26
, Issue.34
, pp. 5569-5575
-
-
Viale, G.1
Giobbie-Hurder, A.2
Regan, M.M.3
-
12
-
-
84055211756
-
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer
-
COI: 1:CAS:528:DC%2BC3MXhs1CqtrbE, PID: 21998336
-
Bago-Horvath Z, Rudas M, Dubsky P et al (2011) Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res 17(24):7828–7834
-
(2011)
Clin Cancer Res
, vol.17
, Issue.24
, pp. 7828-7834
-
-
Bago-Horvath, Z.1
Rudas, M.2
Dubsky, P.3
-
13
-
-
80051499222
-
MMP-1 expression has an independent prognostic value in breast cancer
-
PID: 21835023
-
Boström P, Söderström M, Vahlberg T et al (2011) MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 11(11):348
-
(2011)
BMC Cancer
, vol.11
, Issue.11
, pp. 348
-
-
Boström, P.1
Söderström, M.2
Vahlberg, T.3
-
14
-
-
50249145879
-
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
-
COI: 1:CAS:528:DC%2BD1cXlsV2qt7Y%3D, PID: 18451232
-
Brennan DJ, Rexhepaj E, O’Brien SL et al (2008) Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14(9):2681–2689
-
(2008)
Clin Cancer Res
, vol.14
, Issue.9
, pp. 2681-2689
-
-
Brennan, D.J.1
Rexhepaj, E.2
O’Brien, S.L.3
-
15
-
-
0030010161
-
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer
-
COI: 1:STN:280:DyaK1M%2FjsFSmtw%3D%3D, PID: 9816207
-
Brown RW, Allred CD, Clark GM et al (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2(3):585–592
-
(1996)
Clin Cancer Res
, vol.2
, Issue.3
, pp. 585-592
-
-
Brown, R.W.1
Allred, C.D.2
Clark, G.M.3
-
16
-
-
84874565337
-
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse
-
COI: 1:STN:280:DC%2BC3s%2FhtF2qug%3D%3D, PID: 23022996
-
Cancello G, Maisonneuve P, Rotmensz N et al (2013) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24(3):661–668
-
(2013)
Ann Oncol
, vol.24
, Issue.3
, pp. 661-668
-
-
Cancello, G.1
Maisonneuve, P.2
Rotmensz, N.3
-
17
-
-
84871715926
-
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
-
PID: 22704459
-
De Cicco C, Gilardi L, Botteri E et al (2013) Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast 22(1):39–43
-
(2013)
Breast
, vol.22
, Issue.1
, pp. 39-43
-
-
De Cicco, C.1
Gilardi, L.2
Botteri, E.3
-
18
-
-
33744938180
-
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome
-
COI: 1:CAS:528:DC%2BD28XksF2it78%3D, PID: 16707478
-
Dolled-Filhart M, McCabe A, Giltnane J et al (2006) Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66(10):5487–5494
-
(2006)
Cancer Res
, vol.66
, Issue.10
, pp. 5487-5494
-
-
Dolled-Filhart, M.1
McCabe, A.2
Giltnane, J.3
-
19
-
-
77955097761
-
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy
-
COI: 1:CAS:528:DC%2BC3cXpsVCitr0%3D, PID: 20576719
-
Dumontet C, Krajewska M, Treilleux I et al (2010) BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 16(15):3988–3997
-
(2010)
Clin Cancer Res
, vol.16
, Issue.15
, pp. 3988-3997
-
-
Dumontet, C.1
Krajewska, M.2
Treilleux, I.3
-
20
-
-
84881207711
-
Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya
-
PID: 23074382
-
Ermiah E, Buhmeida A, Abdalla F et al (2012) Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya. J Cancer 3:421–431
-
(2012)
J Cancer
, vol.3
, pp. 421-431
-
-
Ermiah, E.1
Buhmeida, A.2
Abdalla, F.3
-
21
-
-
84876296473
-
Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis
-
COI: 1:STN:280:DC%2BC3szosFKjuw%3D%3D, PID: 23411686
-
Gamucci T, Vaccaro A, Ciancola F et al (2013) Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 139(5):853–860
-
(2013)
J Cancer Res Clin Oncol
, vol.139
, Issue.5
, pp. 853-860
-
-
Gamucci, T.1
Vaccaro, A.2
Ciancola, F.3
-
22
-
-
43249092223
-
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
-
COI: 1:STN:280:DC%2BD1c3nvFSrsA%3D%3D, PID: 18174609
-
Gluz O, Nitz UA, Harbeck N et al (2008) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19(5):861–870
-
(2008)
Ann Oncol
, vol.19
, Issue.5
, pp. 861-870
-
-
Gluz, O.1
Nitz, U.A.2
Harbeck, N.3
-
23
-
-
84878755125
-
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
-
COI: 1:CAS:528:DC%2BC3sXptVCju7o%3D, PID: 23674192
-
Inwald EC, Klinkhammer-Schalke M, Hofstädter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139(2):539–552
-
(2013)
Breast Cancer Res Treat
, vol.139
, Issue.2
, pp. 539-552
-
-
Inwald, E.C.1
Klinkhammer-Schalke, M.2
Hofstädter, F.3
-
24
-
-
80055061495
-
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
-
COI: 1:CAS:528:DC%2BC38Xms1ClsA%3D%3D, PID: 22044691
-
Jacquemier J, Boher JM, Roche H et al (2011) Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 13(6):R109
-
(2011)
Breast Cancer Res
, vol.13
, Issue.6
, pp. 109
-
-
Jacquemier, J.1
Boher, J.M.2
Roche, H.3
-
25
-
-
68349108221
-
Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
-
PID: 19405945
-
Jacquemier J, Charafe-Jauffret E, Monville F et al (2009) Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 11(2):R23
-
(2009)
Breast Cancer Res
, vol.11
, Issue.2
, pp. 23
-
-
Jacquemier, J.1
Charafe-Jauffret, E.2
Monville, F.3
-
26
-
-
78649604771
-
The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study
-
Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer 3(10):664
-
(2010)
BMC Cancer
, vol.3
, Issue.10
, pp. 664
-
-
Jung, S.Y.1
Jeong, J.2
Shin, S.H.3
-
27
-
-
77950863930
-
Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer
-
PID: 20143153
-
Jung SY, Kim HY, Nam BH et al (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120(3):627–637
-
(2010)
Breast Cancer Res Treat
, vol.120
, Issue.3
, pp. 627-637
-
-
Jung, S.Y.1
Kim, H.Y.2
Nam, B.H.3
-
28
-
-
79959541914
-
Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience
-
COI: 1:STN:280:DC%2BC3MnjtlCnsg%3D%3D, PID: 21596514
-
Kim RG, Kim EK, Kim HA et al (2011) Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol 37(7):629–634
-
(2011)
Eur J Surg Oncol
, vol.37
, Issue.7
, pp. 629-634
-
-
Kim, R.G.1
Kim, E.K.2
Kim, H.A.3
-
29
-
-
77957924786
-
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
-
Kwon JH, Kim YJ, Lee KW et al (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 15(10):557
-
(2010)
BMC Cancer
, vol.15
, Issue.10
, pp. 557
-
-
Kwon, J.H.1
Kim, Y.J.2
Lee, K.W.3
-
30
-
-
77955770298
-
Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival
-
PID: 20574671
-
Lee JA, Kim KI, Bae JW et al (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123(1):177–187
-
(2010)
Breast Cancer Res Treat
, vol.123
, Issue.1
, pp. 177-187
-
-
Lee, J.A.1
Kim, K.I.2
Bae, J.W.3
-
31
-
-
34248177270
-
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
-
Lee KH, Im SA, Oh DY et al (2007) Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 12(7):63
-
(2007)
BMC Cancer
, vol.12
, Issue.7
, pp. 63
-
-
Lee, K.H.1
Im, S.A.2
Oh, D.Y.3
-
32
-
-
84896804476
-
Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study
-
PID: 24498305
-
Li FY, Wu SG, Zhou J et al (2014) Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS ONE 9(2):e87264
-
(2014)
PLoS ONE
, vol.9
, Issue.2
, pp. 87264
-
-
Li, F.Y.1
Wu, S.G.2
Zhou, J.3
-
33
-
-
80051897884
-
Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
-
COI: 1:CAS:528:DC%2BC3MXht1yju7zF, PID: 21642658
-
Lin CH, Lu YS, Huang CS et al (2011) Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients? J Clin Pathol 64(9):781–787
-
(2011)
J Clin Pathol
, vol.64
, Issue.9
, pp. 781-787
-
-
Lin, C.H.1
Lu, Y.S.2
Huang, C.S.3
-
34
-
-
67649873218
-
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer
-
COI: 1:CAS:528:DC%2BD1MXotVKgtLY%3D, PID: 19513072
-
Loussouarn D, Campion L, Leclair F et al (2009) Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer 101(1):166–173
-
(2009)
Br J Cancer
, vol.101
, Issue.1
, pp. 166-173
-
-
Loussouarn, D.1
Campion, L.2
Leclair, F.3
-
35
-
-
84925222880
-
Impact of sentinel node tumor burden on outcome of invasive breast cancer patients
-
COI: 1:STN:280:DC%2BC2M%2FntVyisg%3D%3D, PID: 25179162
-
Meattini I, Desideri I, Saieva C et al (2014) Impact of sentinel node tumor burden on outcome of invasive breast cancer patients. Eur J Surg Oncol 40(10):1195–1202
-
(2014)
Eur J Surg Oncol
, vol.40
, Issue.10
, pp. 1195-1202
-
-
Meattini, I.1
Desideri, I.2
Saieva, C.3
-
36
-
-
0036473059
-
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
-
COI: 1:CAS:528:DC%2BD38XisFOls78%3D, PID: 11875707
-
Michalides R, van Tinteren H, Balkenende A et al (2002) Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 86(3):402–408
-
(2002)
Br J Cancer
, vol.86
, Issue.3
, pp. 402-408
-
-
Michalides, R.1
van Tinteren, H.2
Balkenende, A.3
-
37
-
-
79960841940
-
Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients
-
PID: 20803240
-
Naoi Y, Kishi K, Tanei T et al (2011) Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat 128(3):633–641
-
(2011)
Breast Cancer Res Treat
, vol.128
, Issue.3
, pp. 633-641
-
-
Naoi, Y.1
Kishi, K.2
Tanei, T.3
-
38
-
-
84922653564
-
Prognostic significance of the Ki67 scoring categories in breast cancer subgroups
-
COI: 1:CAS:528:DC%2BC2cXhvFGms78%3D, PID: 24492237
-
Niikura N, Masuda S, Kumaki N et al (2014) Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer. 14(5):323–329.e3
-
(2014)
Clin Breast Cancer.
, vol.14
, Issue.5
, pp. 323-329
-
-
Niikura, N.1
Masuda, S.2
Kumaki, N.3
-
39
-
-
77955203082
-
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
-
PID: 22993598
-
Nishimura R, Osako T, Okumura Y et al (2010) Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 1(5):747–754
-
(2010)
Exp Ther Med
, vol.1
, Issue.5
, pp. 747-754
-
-
Nishimura, R.1
Osako, T.2
Okumura, Y.3
-
40
-
-
84896549618
-
-
Rocca A, Bravaccini S, Scarpi E et al. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat. 2014; 144(2):307–318. Erratum in: Breast Cancer Res Treat. 2014; 144(2):319
-
Rocca A, Bravaccini S, Scarpi E et al. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat. 2014; 144(2):307–318. Erratum in: Breast Cancer Res Treat. 2014; 144(2):319
-
-
-
-
41
-
-
84892822130
-
The potential utility of geminin as a predictive biomarker in breast cancer
-
COI: 1:CAS:528:DC%2BC3sXhvVOnsLnK, PID: 24292956
-
Sundara Rajan S, Hanby AM, Horgan K et al (2014) The potential utility of geminin as a predictive biomarker in breast cancer. Breast Cancer Res Treat 143(1):91–8
-
(2014)
Breast Cancer Res Treat
, vol.143
, Issue.1
, pp. 91-98
-
-
Sundara Rajan, S.1
Hanby, A.M.2
Horgan, K.3
-
42
-
-
84871417491
-
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
-
PID: 22934555
-
Synnestvedt M, Borgen E, Russnes HG et al (2013) Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncol 52(1):91–101
-
(2013)
Acta Oncol
, vol.52
, Issue.1
, pp. 91-101
-
-
Synnestvedt, M.1
Borgen, E.2
Russnes, H.G.3
-
43
-
-
33748285041
-
Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients
-
PID: 16932023
-
Treré D, Ceccarelli C, Migaldi M et al (2006) Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients. Appl Immunohistochem Mol Morphol 14(3):314–323
-
(2006)
Appl Immunohistochem Mol Morphol
, vol.14
, Issue.3
, pp. 314-323
-
-
Treré, D.1
Ceccarelli, C.2
Migaldi, M.3
-
44
-
-
59349092369
-
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
-
Tutt A, Wang A, Rowland C et al (2008) Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer 21(8):339
-
(2008)
BMC Cancer
, vol.21
, Issue.8
, pp. 339
-
-
Tutt, A.1
Wang, A.2
Rowland, C.3
-
45
-
-
64649087149
-
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
-
PID: 19342238
-
Wiesner FG, Magener A, Fasching PA et al (2009) Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18(2):135–141
-
(2009)
Breast
, vol.18
, Issue.2
, pp. 135-141
-
-
Wiesner, F.G.1
Magener, A.2
Fasching, P.A.3
-
46
-
-
84865706969
-
Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China
-
COI: 1:CAS:528:DC%2BC38Xht1ymt7fN, PID: 22625227
-
Xue C, Wang X, Peng R et al (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 103(9):1679–1687
-
(2012)
Cancer Sci
, vol.103
, Issue.9
, pp. 1679-1687
-
-
Xue, C.1
Wang, X.2
Peng, R.3
-
47
-
-
84880043222
-
Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens
-
PID: 22362219
-
Yamamoto S, Ibusuki M, Yamamoto Y et al (2013) Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer. 20(3):262–270
-
(2013)
Breast Cancer.
, vol.20
, Issue.3
, pp. 262-270
-
-
Yamamoto, S.1
Ibusuki, M.2
Yamamoto, Y.3
-
48
-
-
84876141612
-
Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population
-
PID: 23483340
-
Zhang X, Li P, Ma W et al (2013) Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population. Sci China Life Sci 56(4):335–340
-
(2013)
Sci China Life Sci
, vol.56
, Issue.4
, pp. 335-340
-
-
Zhang, X.1
Li, P.2
Ma, W.3
-
49
-
-
84925415466
-
Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study
-
PID: 25170613
-
Zong Y, Zhu L, Wu J et al (2014) Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One 9(8):e95629
-
(2014)
PLoS One
, vol.9
, Issue.8
, pp. 95629
-
-
Zong, Y.1
Zhu, L.2
Wu, J.3
-
50
-
-
84962581651
-
The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value. Appl Immunohistochem Mol Morphol
-
Cho U, Kim HE, Oh WJ et al (2015) The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value. Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000164
-
(2015)
doi:10.1097/PAI.0000000000000164
-
-
Cho, U.1
Kim, H.E.2
Oh, W.J.3
-
51
-
-
48849096940
-
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
-
COI: 1:STN:280:DC%2BD1crgs1Kruw%3D%3D, PID: 18455396
-
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17(4):323–334
-
(2008)
Breast
, vol.17
, Issue.4
, pp. 323-334
-
-
Stuart-Harris, R.1
Caldas, C.2
Pinder, S.E.3
Pharoah, P.4
-
52
-
-
84939423024
-
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
-
COI: 1:STN:280:DC%2BC2MfgsFWrsw%3D%3D, PID: 25939896
-
Coates AS, Winer EP, Goldhirsch A et al (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 26:1533–1546
-
(2015)
Ann Oncol.
, vol.26
, pp. 1533-1546
-
-
Coates, A.S.1
Winer, E.P.2
Goldhirsch, A.3
-
53
-
-
66849140730
-
Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer
-
COI: 1:CAS:528:DC%2BD1MXmtlyit74%3D, PID: 19436038
-
Cheang MC, Chia SK, Voduc D et al (2009) Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 736-750
-
-
Cheang, M.C.1
Chia, S.K.2
Voduc, D.3
-
54
-
-
84885366396
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
COI: 1:STN:280:DC%2BC3sbitVWltg%3D%3D, PID: 23970019
-
Senkus E, Kyriakides S, Penault-Llorca F et al (2013) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6:vi7–23
-
(2013)
Ann Oncol
, vol.24 Suppl 6
, pp. 7-23
-
-
Senkus, E.1
Kyriakides, S.2
Penault-Llorca, F.3
-
55
-
-
84942995239
-
-
. Accessed 12 April 2014
-
http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 12 April 2014
-
-
-
-
56
-
-
81555208345
-
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
-
COI: 1:CAS:528:DC%2BC3MXhsFantrbF, PID: 21960707
-
Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664
-
(2011)
J Natl Cancer Inst
, vol.103
, Issue.22
, pp. 1656-1664
-
-
Dowsett, M.1
Nielsen, T.O.2
A’Hern, R.3
-
57
-
-
84891459472
-
An international Ki67 reproducibility study
-
PID: 24203987
-
Polley MY, Leung SC, McShane LM et al (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897–1906
-
(2013)
J Natl Cancer Inst
, vol.105
, Issue.24
, pp. 1897-1906
-
-
Polley, M.Y.1
Leung, S.C.2
McShane, L.M.3
-
58
-
-
84930177652
-
An international study to increase concordance in Ki67 scoring
-
PID: 25698062
-
Polley MY, Leung SC, Gao D et al (2015) An international study to increase concordance in Ki67 scoring. Mod Pathol 28(6):778–786
-
(2015)
Mod Pathol
, vol.28
, Issue.6
, pp. 778-786
-
-
Polley, M.Y.1
Leung, S.C.2
Gao, D.3
-
59
-
-
67649983962
-
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
-
COI: 1:CAS:528:DC%2BD1MXosVehs7w%3D, PID: 19380452
-
Penault-Llorca F, André F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17):2809–2815
-
(2009)
J Clin Oncol
, vol.27
, Issue.17
, pp. 2809-2815
-
-
Penault-Llorca, F.1
André, F.2
Sagan, C.3
-
60
-
-
84890879306
-
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer
-
PID: 24314620
-
Criscitiello C, Disalvatore D, De Laurentiis M et al (2014) High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Breast 23(1):69–75
-
(2014)
Breast
, vol.23
, Issue.1
, pp. 69-75
-
-
Criscitiello, C.1
Disalvatore, D.2
De Laurentiis, M.3
-
61
-
-
80055021887
-
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
-
COI: 1:STN:280:DC%2BC3MbjvFeluw%3D%3D, PID: 21970880
-
Sahebjam S, Aloyz R, Pilavdzic D et al (2011) Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 105(9):1342–1345
-
(2011)
Br J Cancer
, vol.105
, Issue.9
, pp. 1342-1345
-
-
Sahebjam, S.1
Aloyz, R.2
Pilavdzic, D.3
-
62
-
-
84859434967
-
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas
-
COI: 1:CAS:528:DC%2BC38XltFKisLs%3D, PID: 22173289
-
Acs G, Esposito NN, Kiluk J et al (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol 25(4):556–566
-
(2012)
Mod Pathol
, vol.25
, Issue.4
, pp. 556-566
-
-
Acs, G.1
Esposito, N.N.2
Kiluk, J.3
-
63
-
-
84903280055
-
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow
-
PID: 24649291
-
Aktas B, Bankfalvi A, Heubner M et al (2013) Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow. Mol Clin Oncol 1(6):1049–1054
-
(2013)
Mol Clin Oncol
, vol.1
, Issue.6
, pp. 1049-1054
-
-
Aktas, B.1
Bankfalvi, A.2
Heubner, M.3
-
64
-
-
84922309911
-
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
-
Thaker NG, Hoffman KE, Stauder MC et al (2015) The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus 30(4):36
-
(2015)
Springerplus
, vol.30
, Issue.4
, pp. 36
-
-
Thaker, N.G.1
Hoffman, K.E.2
Stauder, M.C.3
-
65
-
-
84934437431
-
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
-
PID: 25932962
-
Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, Huston A, Ling M, Hicks DG (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28(7):921–931
-
(2015)
Mod Pathol
, vol.28
, Issue.7
, pp. 921-931
-
-
Turner, B.M.1
Skinner, K.A.2
Tang, P.3
Jackson, M.C.4
Soukiazian, N.5
Shayne, M.6
Huston, A.7
Ling, M.8
Hicks, D.G.9
-
66
-
-
81155133281
-
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer
-
PID: 21990413
-
Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278
-
(2011)
J Clin Oncol
, vol.29
, Issue.32
, pp. 4273-4278
-
-
Cuzick, J.1
Dowsett, M.2
Pineda, S.3
-
67
-
-
84884704047
-
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
-
PID: 24035531
-
Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14(11):1067–1076
-
(2013)
Lancet Oncol
, vol.14
, Issue.11
, pp. 1067-1076
-
-
Sgroi, D.C.1
Sestak, I.2
Cuzick, J.3
|